One hundred and seventeen years after Alzheimer described the condition that bears his name, the first treatments have been identified which appear to modify its course.1 2 These treatments are monoclonal antibodies which clear one of the presumed pathogenic proteins (amyloid) from the brain. This is welcome progress, but it has come with concerns including the extent of benefits and risks of potentially significant harm.3 Further concerns are the potential economic impact and whether health services can deliver these treatments given the number of people living with Alzheimer’s disease. Estimates of the numbers of people who might receive them are vital to inform preparation of services. The JNNP paper by Dobson et al is therefore welcome.4 Previous work has applied the exclusion criteria used in trials to clinic populations to estimate demand. Dobson et al extend this. They report data from…
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Underwood, B. R. | August 16, 2024